Media OutReach
Bora 3Q25 Delivers Renewed Profitability as Efficiency and Scale Improves
Strategic realignment powering Bora’s dual-engine businesses model
HONG KONG SAR – Media OutReach Newswire – 13 November 2025 – Bora Pharmaceuticals (TWSE: 6472) today announced its financial results and operational highlights for third quarter of 2025.
Quarterly Business and Financial Highlights
- Company reported quarterly basic EPS of NT$5.09, with a loss per share of NT$1.49 from discontinued operations. Operating income reached NT$1,063 million and net income for continued operations came in at NT$822 million, resulting in quarterly EBITDA of NT$1,283 million, well on track to reclaim 2023 core P&L indicators.
- By the end of 3Q25, Bora’s operational integration and strategic streamlining efforts have been fully executed, meeting all targeted objectives. This milestone has led to a record-high CDMO business profitability, clear evidence that Bora’s dual-engine model is now entering its next phase of balanced but scalable growth.
- Fueled by expanded capacity and the addition of new dosage forms, Bora’s CDMO business grew 56.5% year-to-date through 3Q25, reaching over NT$7.3 billion and returning to a sequential growth trajectory.
- Pharma sales revenues fluctuated as legacy inventory phased out, and new products are still awaiting approvals. Generics portfolio competitiveness remains a key focus area in the near term. Led by Vigafyde, Bora’s rare disease portfolio continued to gain impressive market share with the vigabatrin franchise across three dosage forms continues. The Company targets to file its next specialty pharma product by year end to accelerate the rare neurology disease business. The Company also targets to market branded Deflazacort tablets by 2025 year end as a new driver for the business.
- The Company expects NTD to remain in the range of NTD 30-31 per USD for its operational planning.
- Share capital increased 19.99% during the quarter from stock dividend distribution, employee stock option exercise and convertible bond conversions.
- The Board approved Level-1 ADR issuance with each ADR share corresponding to 1/5 common share and total ADR issuance <10% of outstanding shares to enhanced market trust and investor service.
Mr. Bobby Sheng, Chairman of Bora Group, stated, “Bora executed a record level of post-merger CAPEX investment in 2025 and we are progressing in line with our strategic plan. We have expanded our Maryland aseptic fill/finish capacity by approximately 10% while solid and liquid dosage capacity in Minneapolis and Mississauga grew around 3%. The investments allowed Bora to increase our operational efficiency and increase revenue per headcount in the CDMO business by ~30% during the quarter compared to beginning of the year.
The CDMO backlog rose to US$296 million, driven by 27 new contracts and over 20 new molecules year-to-date, providing solid visibility into 2026 with 72% commercialized projects. Bora continues to leverage a unified CDMO network to enhance cost competitiveness for our very own Upsher-Smith generics portfolio, while paving the way for selective in-house manufacturing of specialty assets in the U.S.
As we look ahead, Bora is entering a phase of disciplined expansion and broader global recognition. Across our CDMO facilities in Asia and North America, we continue to actively navigate tariff and geopolitical challenges and turn them into new opportunities, strengthening supply chain resilience, and deepening collaboration with multinational partners.
On the pharma sales side, we continue to shed legacy low margin generics, increase our cashflow, and focus on our high-value generics pipeline, with certain PIV opportunities progressing to maturity in 2026. We remain dedicated on enhancing portfolio quality and increasing our Branded assets through selective specialty drugs, in order to build a more predictable and margin-accretive revenue base that mitigates product commoditization and price degredation.
In parallel, we are expanding our capital-market reach into the United States through the OTCQX Level-1 ADR program. We believe the Bora ADR will improve access and transparency for global institutional investors, while enabling overseas employees to participate in Bora’s growth. With no dilution and increasing visibility, we are laying the foundation for a stronger and more global 2026, defined by scaled growth, operational synergies, and increasing investor confidence.
3Q2025 Operational Achievements & Full Year Outlook
Global CDMO Operations
Global CDMO Operations (excluding intercompany orders from Upsher-Smith) revenues arrived at NT$1.78 billion in the third quarter and back to the sequential growth zone, representing approximately 37.13% of total revenue. A total of 418 million doses were developed and manufactured. Revenue contribution from global top 20 pharmaceutical companies remained steady at approximately 33%. Year-to-date, CDMO revenues grew 18.98% over last year and reached NT$5.27 billion. Bora continues to execute on expanding this customer base to enhance business visibility and stability.
- As the Company ramps up its Maple Grove site, the momentum for U.S. manufacturing has been encouraging. Several clinical-stage clients are now transitioning into long-term strategic partnerships, with project scale and client size both increasing. Maple Grove is well positioned to be the Center of Excellence for scale-up and U.S. supply-chain integration for Bora.
- Large molecule CDMO operation revenues saw nearly 50% increase over the previous quarter, driven by one new ADC client and several change orders in addition to Cipla’s own labeled product launch under the collaboration agreement. Positioned as a one-stop CDMO platform alongside Bora Pharmaceuticals, Bora Biologics is now fully accelerating its CDMO operations
Pharma Sales Operations
Pharma Sales Operations in the third quarter reached a revenue of NT$3.02 billion, down 6.4% YoY, primarily due to discontinuing several products under significant pricing pressure. Pharma Sales accounted for approximately 62.83% of total revenues.
- Discontinued loss per share (from the closure of the Plymouth production area) reflected the clearance sale of higher-cost inventories from Upsher-Smith’s legacy generics and internal supply transfer delayed by regulatory hurdles. These inventory clearance sales are now nearing completion. The greater-than-expected pricing pressure across our low margin generics reinforces the need to accelerate Bora’s transition toward higher-value and Branded specialty pharma products.
- The Vigabatrin franchise market share expansion continues with the “total patient” indicator seeing breakthrough in October.
- Bora continues to focus on DEE (Developmental and Epileptic Encephalopathies), where legacy compounds fail to meet significant unmet needs. The market is poised for new NCE entrants, expanding the addressable opportunity to roughly US$10 billion over the next 3–5 years. Bora aims to capture this growth through a Ready-to-Use 505(b)(2) pipeline and branded generics.
Recent Investor Conference
Bora will host an English online earnings call at 8:00 p.m. Taiwan time on Nov. 13th, 2025, followed by an investor conference hosted by Taishin Securities at the Regent Taipei at 2:30 p.m. on Nov. 14th, 2025. Both events will cover the company’s Q3’25 financial and business results and outlook.
English Online Earnings Presentation Link: https://events.q4inc.com/attendee/477519089
Bora will participate in the JP Morgan Healthcare Conference in January in San Francisco. For 1:1 meetings with management, please contact your JP Morgan representative.
Bora 2025 Earnings Schedule
Q4 2025: Expected in the 2nd week of March 2026
Hashtag: #BoraPharmaceuticals
The issuer is solely responsible for the content of this announcement.
About Bora
Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients’ quality of life.
By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. For more information, visit www.bora-corp.com.
Disclaimer:
This document and the accompanying information may contain forward-looking statements. All statements regarding the company’s future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company’s control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.
Media OutReach
New Battery-Operated Bluetooth® Controller Enables Truly Mobile, Plug-and-Play Access
Powerful Performance from Just Four AA Batteries
Powered by only four AA batteries, the controller delivers over two years of operation when driving a 12VDC latch, dramatically reducing maintenance compared to typical battery-powered systems. Its high-efficiency internal buck/boost technology ensures optimal power delivery while using fewer batteries than conventional approaches.
Redundant Power for Critical Access
When batteries eventually require replacement, Southco has designed built-in redundancy to avoid downtime. A power override port—compatible today with a 9V battery and adaptable for future power inputs—provides temporary power so users can unlock the enclosure, replace batteries, and restore full operation quickly.
Smart Monitoring Through the Keypanion® App
Battery health is continuously monitored through Southco’s Keypanion® App, which alerts users well before battery replacement is needed, reducing the likelihood of emergency access situations.
For Original Equipment Manufacturers building their own mobile apps, Southco also offers a Software Development Kit (SDK), enabling seamless integration between the controller and customers’ existing digital ecosystems.
Designed for Real-World Enclosures
A removable battery pod allows fast, frustration-free battery changes—especially valuable in tight, hard-to-reach installations. Users can slide out the cartridge, load all batteries at once, and reinsert it without navigating cramped enclosure spaces.
The controller also features true plug-and-play installation. Simply insert the four AA batteries, plug in the latch, and the system is ready to operate—no wire splicing, no external power, and no additional electronics required.
Mobile Access Without Security Infrastructure
With the Keypanion® App, users can activate, manage, and share access directly from a mobile device. There is no server setup, no IT overhead, and no wiring required. Permissions can be granted or revoked instantly, replacing physical keys with secure digital control.
New Possibilities for Remote and Unpowered Applications
This combination of self-contained power, Bluetooth® connectivity, and mobile access expands what designers can do in environments once considered too challenging for electronic access. Ideal applications include:
- Remote and public installations without external power
- Retrofit upgrades for existing unpowered enclosures
- Critical infrastructure such as fiber optic boxes requiring secure, monitored access
By eliminating the need for solar panels, power drops, or complex security systems, Southco’s Battery-Operated Bluetooth® Controller reduces material costs and gives OEMs far greater design freedom.
A Flexible, Future-Ready Solution
Beyond immediate use cases, the power override port helps engineers address mechanical override considerations by providing a reliable method to restore power and gain entry when traditional power sources fail—a major benefit noted by early customer feedback.
The Battery-Operated Single Output Bluetooth® Controller provides a strong foundation for the next generation of remote access solutions, delivering convenience, efficiency, and security in one streamlined device.
For more information, please visit www.southco.com or email Southco’s 24/7 customer service team at in**@*****co.com.
Hashtag: #Southco
The issuer is solely responsible for the content of this announcement.
About Southco
Southco, Inc. is the leading global designer and manufacturer of engineered access solutions. From quality and performance to aesthetics and ergonomics, we understand that first impressions are lasting impressions in product design. For over 80 years, Southco has helped the world’s most recognized brands create value for their customers with innovative access solutions designed to enhance the touch points of their products in transportation and industrial applications, medical equipment, data centers and more. With unrivalled engineering resources, innovative products and a dedicated global team, Southco delivers the broadest portfolio of premium access solutions available to equipment designers throughout the world.
Southco Asia Limited
2401, Tower 2, Ever Gain Plaza
88 Container Port Road, Kwai Chung
Hong Kong
Media OutReach
OTIC Hearing Unveils New Audiological Milestones In Hong Kong: Launching The Award-Winning Oticon Zeal And The Pediatric Oticon Play SI Platforms
Developed to mimic natural brain sound processing, these platforms represent a major leap forward in treating hearing loss across all ages. Together, the Oticon Zeal and Oticon Play SI lines bring the next evolution of BrainHearing™ technology to Hong Kong. Headlining this release is the custom-molded Oticon Zeal, which recently won the 2026 Red Dot Design Award—one of the world’s most prestigious international seals of design quality and innovation. By introducing these dual systems, OTIC Hearing effortlessly bridges the gap between invisible aesthetics for image-conscious adults and robust learning support for developing children.
Oticon Zeal: Setting a New Standard for Invisible Hearing Technology
For many adults experiencing mild-to-moderate hearing impairment, the social stigma of traditional behind-the-ear devices remains a major deterrent to seeking intervention. Oticon Zeal rewrites this narrative with its NXT In-the-Ear (ITE) style.
Individually sculpted to fit deeply within the user’s ear canal, Oticon Zeal achieves absolute invisibility when viewed from a frontal profile, presenting an ultra-compact faceplate only when observed directly from the side. This is achieved via advanced 3D modeling and laser-sculpting technology, which integrates complex components into an exceptionally small shell without compromising on features.
Overcoming a historic limitation of invisible hearing aids, the frequent changing of tiny disposable batteries; Oticon Zeal introduces an integrated lithium-ion rechargeable power cell. The system delivers up to 20 hours of continuous battery life on a single charge. Every device pairs with a desktop SmartCharger that functions as a mobile power bank. For urgent situations, a fast-charging protocol provides four hours of operational power from a brief 15-minute charge.
Deep Neural Network 2.0 Processing
At the core of Oticon Zeal’s processing is an on-chip, second-generation AI engine. Driven by an updated Deep Neural Network (DNN) 2.0 and a SuddenSound Stabilizer, the processor scans and balances the surrounding soundscape hundreds of times per second.
Standard digital hearing systems often rely on narrow, directional microphones that isolate a single speaker while dampening peripheral noise. This artificial restriction deprives the brain of essential contextual audio, creating cognitive strain and mental fatigue.
In contrast, Oticon Zeal’s AI preserves a natural, 360-degree open soundscape. By suppressing sudden background noises by up to 12 decibels while actively enhancing speech clarity by up to 6 decibels, the platform allows the brain to naturally choose which sound source to focus on, even within high-volume environments like corporate meetings or crowded restaurants.
Oticon Play SI: Purpose-Built Pediatric Care for Growing Minds
Alongside the adult-focused Oticon Zeal, OTIC Hearing is introducing Oticon Play SI to deliver specialized auditory care tailored directly to the unique developmental requirements of growing children. The Oticon Play SI family is optimized to deliver a rich, high-fidelity sound stream essential for language acquisition, academic success, and social confidence.
Children live dynamic lives, moving rapidly from quiet homes to noisy classrooms and playgrounds. Oticon Play SI addresses this volatility by becoming the industry’s first pediatric family to combine a second-generation AI processing core with integrated 4D user-intent sensors.
These sensors track physical head movements, body activity levels, and localized acoustic shifts. The system automatically adjusts its processing parameters in real time, ensuring the child remains clearly connected to teacher instructions, parental guidance, and peer interactions.
To withstand childhood adventures, Oticon Play SI features an IP68-certified robust housing, offering maximum protection against dust, moisture, and debris. This fully sealed architecture safeguards delicate internal circuitry from sweat, rain, and accidental spills. Available in versatile miniRITE R and miniBTE R styles, the lineup offers a broad array of 12 expressive color choices, seven colored ear-hook options, and custom decorative stickers, empowering children to wear their devices with personal pride.
Advanced Digital Connectivity
To seamlessly interface with today’s digital environment, both Oticon Zeal and Oticon Play SI feature state-of-the-art streaming protocols. Utilizing advanced Bluetooth® LE Audio technology, both product families deliver low-energy direct audio streaming from smartphones, tablets, laptops, and smart televisions, keeping users connected without draining device batteries.
Hashtag: #OTIC
The issuer is solely responsible for the content of this announcement.
About OTIC Hearing
Established in 2005, OTIC Hearing (Otic Hearing & Speech Centre) is one of the largest, most trusted hearing care clinical groups in Hong Kong. Guided by a corporate philosophy of “People First”, OTIC Hearing manages a comprehensive network of eight specialized service centers strategically distributed across Hong Kong Island, Kowloon, and the New Territories. Clinics are located in Central, Causeway Bay, Jordan, Tsim Sha Tsui, Kwun Tong, Shatin, Tsuen Wan, and Yuen Long.
As the exclusive distributor of Oticon A/S in Hong Kong, OTIC Hearing pairs world-leading technology with an elite team of clinical audiologists and technical hearing specialists. Every facility is fully outfitted with advanced diagnostic and testing instrumentation, allowing the clinical team to deliver precise hearing assessments, custom-fitting protocols, and specialized pediatric auditory rehabilitation. OTIC Hearing maintains a strict commitment to ongoing professional training, ensuring that every client receives a supportive, accurate rehabilitation journey designed to restore lifestyle confidence.
Media OutReach
Pacific Century Premium Developments Limited announces interim results for six months ended June 30, 2026
2026 Interim Results – Financial Highlights
(Figures for the corresponding period in 2025 are shown in brackets)
- Consolidated revenue: HK$593 million (HK$ 636 million)
- Consolidated net loss attributable to equity holders of the Company: HK$189 million (HK$ 249 million)
- Basic loss per share: 9.28 HK cents (12.23 HK cents)
- No interim dividend (No interim dividend)
Pacific Century Premium Developments Limited (“PCPD”, SEHK: 00432) announced its interim results for the six months ended June 30, 2026.
The consolidated revenue of PCPD and its subsidiaries (together, the “Group”) amounted to HK$ 593 million, compared to HK$ 636 million for the corresponding period of 2025.
The Group’s consolidated loss attributable to equity holders of the Company for the first six months of 2026 totalled HK$ 189 million, compared to a net loss of HK$249 million for the corresponding period last year. Basic loss per share for the six months ended June 30, 2026 was 9.28 Hong Kong cents, compared to a loss per share of 12.23 Hong Kong cents for the corresponding period of 2025.
The Board of Directors did not declare an interim dividend for the first half of 2026.
For the first half of 2026, the Group delivered encouraging results as we built on our core strengths and benefited from resilient demand across the markets in which we operate. During the period, we also took steps to enhance our portfolio, including the disposals of two investment assets. These initiatives are expected to strengthen the Group’s financial position and reinforce its long-term growth.
Our operations in Japan performed well despite some moderation in tourism demand, shaped by changes in the composition of international visitors and fluctuations in travel demand. Park Hyatt Niseko, Hanazono, our hospitality business in Niseko, Hokkaido, delivered a stable performance with healthy occupancy and room rates, while our ski operations remained a key contributor to the Group’s results. Earnings from our recreational facilities, ski lifts, equipment rentals, “Hanazono EDGE” (a restaurant and entertainment centre) and Niseko International Snowsports Schoolcontinued togrow year-on-year. We will stay focused on establishing Niseko Hanazono Resort as a world-class, all-season luxury destination and remain optimistic about its long-term development.
On March 16, 2026, the Group announced the sale of its entire interest in Pacific Century Place, Jakarta (“PCP Jakarta”) in Indonesia. The transaction, at a total consideration of US$400 million, was completed on June 8, 2026. Notwithstanding the disposal, the Group will continue to provide property management services in respect of PCP Jakarta.
On February 13, 2026, the Group announced the sale of its entire interest in Midtown Niseko. The transaction, at a total consideration of US$80 million, was completed on May 31, 2026.
The Group formed a strategic alliance with Hotel Properties Limited in Singapore to bring a Four Seasons Resort and Branded Residences to Aquella, a large-scale integrated resort development in Phang Nga. The move represents a significant milestone in PCPD‘s long-term vision of transforming Aquella into an integrated resort destination that effortlessly blends luxury living, recreation and exceptional service.
Central Residence by the Park in Hong Kong was launched for sale in January 2026. As at the end of June, 90.9% of the total available units of the luxury residential project had already been sold. The project will be completed in the latter half of 2026.
Mr. Benjamin Lam, PCPD’s Deputy Chairman and Group Managing Director, said: “The first half of 2026 presented a challenging global environment, characterised by geopolitical tensions including the conflict in the Middle East, inflation, trade uncertainties and concerns over monetary policies. Despite the headwinds, global growth was relatively resilient, while international tourism in many parts of Asia continued to perform steadily. The Group’s core markets in Asia generally remained solid during the period. Tourism demand continued to support Japan and Thailand despite a slightly more measured pace of growth. Improving sentiment in Hong Kong’s property market also provided a more favourable backdrop for our luxury residential development.
In the second half of the year, we will continue to enhance the value of our existing assets while positioning the Group to capitalise on opportunities that support our long-term strategy and create value for our stakeholders.”
Hashtag: #PacificCenturyPremiumDevelopments
The issuer is solely responsible for the content of this announcement.
About PCPD
Pacific Century Premium Developments Limited (“PCPD” or the “Group”, SEHK: 00432) is principally engaged in the development and management of premium-grade property and infrastructure projects as well as premium-grade property investments. PCCW Limited (“PCCW”, SEHK: 00008) is the single largest shareholder of the Group.
